# Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

> **NCT01653028** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 72 (actual)

## Conditions studied

- Myxofibrosarcoma
- Recurrent Adult Soft Tissue Sarcoma
- Recurrent Leiomyosarcoma
- Recurrent Liposarcoma
- Recurrent Malignant Peripheral Nerve Sheath Tumor
- Recurrent Undifferentiated Pleomorphic Sarcoma
- Stage III Soft Tissue Sarcoma AJCC v7
- Stage IV Soft Tissue Sarcoma AJCC v7

## Interventions

- **DRUG:** Alisertib
- **OTHER:** Laboratory Biomarker Analysis

## Key facts

- **NCT ID:** NCT01653028
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-08-22
- **Primary completion:** 2015-08-02
- **Final completion:** —
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2017-11-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01653028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01653028, "Alisertib in Treating Patients With Advanced or Metastatic Sarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01653028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*